← Praram 9 Hospital overview

Praram 9 Hospital vs Bangkok Dusit Medical Services: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Praram 9 Hospital Public Company Limited (PR9.BK)

Q3 2026
▲4

PR9 gains on foreign patients, record Q3 profit forecast, defensive appeal

  • Foreign patient growth supports revenue target Foreign patient growth, especially from the Middle East and Myanmar, supports PR9's 2026 revenue target. This is a key driver because it directly boosts hospital revenue and is a core part of the growth story.

    Foreign patient growth is a fundamental demand driver for PR9's revenue.

  • Brokers forecast record Q3 profit and raise targets Brokers forecast a record Q3 profit and raised their price targets to 22–24.50 baht. This reflects increased optimism and can drive the stock price higher as investors react to analyst upgrades.

    Broker upgrades and profit forecasts directly influence investor sentiment and price targets.

  • New equipment and dialysis centre lift higher-margin cases New equipment and a near-full dialysis centre should lift higher-margin complex cases. This improves profitability by attracting more complex, higher-revenue procedures.

    Operational improvements can enhance margins and profitability.

  • Tighter FDA rules on GLP-1 drugs may benefit hospitals Tighter FDA rules on GLP-1 drugs may push users to hospitals, benefiting PR9. This regulatory change could increase patient volumes for weight-management and related services.

    Regulatory shifts can redirect patient flow to hospitals, boosting demand.

September 2026
▲4

PR9 gains on foreign patients, record Q3 profit forecast, defensive appeal

  • Foreign patient growth supports revenue target Foreign patient growth, especially from the Middle East and Myanmar, supports PR9's 2026 revenue target. This is a key driver because it directly boosts hospital revenue and is a core part of the growth story.

    Foreign patient growth is a fundamental demand driver for PR9's revenue.

  • Brokers forecast record Q3 profit and raise targets Brokers forecast a record Q3 profit and raised their price targets to 22–24.50 baht. This reflects increased optimism and can drive the stock price higher as investors react to analyst upgrades.

    Broker upgrades and profit forecasts directly influence investor sentiment and price targets.

  • New equipment and dialysis centre lift higher-margin cases New equipment and a near-full dialysis centre should lift higher-margin complex cases. This improves profitability by attracting more complex, higher-revenue procedures.

    Operational improvements can enhance margins and profitability.

  • Tighter FDA rules on GLP-1 drugs may benefit hospitals Tighter FDA rules on GLP-1 drugs may push users to hospitals, benefiting PR9. This regulatory change could increase patient volumes for weight-management and related services.

    Regulatory shifts can redirect patient flow to hospitals, boosting demand.

Latest
▲4

Brokers boost PR9 targets as hospital sector turns upcycle

  • KKPS raises PR9 target to 24.50 baht on sector overweight KKPS upgraded the hospital sector to overweight and set a 24.50 baht target for PR9, expecting the state to shift more public health costs to private hospitals. A higher target from a major broker pulls the share price up as investors price in more future profit.

    A new, higher broker target directly raises the price investors are willing to pay for PR9.

  • CGSI sees Q3 profit up 11% and names PR9 a top pick CGSI expects PR9's Q3 2026 net profit to rise 11% from a year earlier and 35% from the prior quarter to 248 million baht, naming it a top pick. A stronger profit forecast supports the share price because investors pay for future earnings.

    A fresh profit forecast and top-pick status are new reasons for investors to buy PR9.

  • Tighter FDA rules on GLP-1 drugs shift users to hospitals Thailand's FDA now classifies GLP-1 weight-loss drugs as specially controlled, pushing users toward hospitals for prescriptions and monitoring. Asia Plus sees PR9 as a standout beneficiary thanks to its cash-paying patients and specialized services, with a 23 baht target.

    This new regulation creates a fresh source of patient visits and revenue for PR9.

  • PR9 named a top Q4 pick and defensive stock amid foreign selling InnovestX picked PR9 as a top stock for Q4 2026, and Asia Plus listed it among low-volatility healthcare names resilient to heavy foreign selling. Being chosen as a safe place to park money can support the share price even when the overall market falls.

    New top-pick and defensive designations attract buying interest that supports PR9's price.

▲4

PR9's foreign-patient growth and record Q3 profit forecast drive the stock

  • Foreign patient growth supports 2026 revenue target PR9 said Q3 2026 is growing on more foreign patients, especially from the Middle East and Myanmar, plus returning Thai patients. Foreign patients are about 27% of the total. Management is confident 2026 revenue will grow by a single-digit percentage as planned. More patients means more revenue, which supports the share price.

    This is the company's own update on the demand driving its revenue, the core reason the stock is moving.

  • Broker forecasts record Q3 profit and a 22 baht target Bualuang expects PR9 to post a record Q3 2026 core profit of 237 million baht, up 7% from a year earlier and 29% from the prior quarter, on revenue of 1.44 billion baht. It keeps a Buy rating and 22 baht target price, seeing a new profit upcycle.

    A record profit forecast and higher target price directly shape what investors expect the stock to be worth.

  • New equipment and dialysis centre lift higher-margin cases The dialysis centre is running near full capacity, and new equipment such as Bi-plane Angiography, Hyperbaric Oxygen Therapy and a Neuro ICU should raise the share of higher-margin complex cases from Q4 2026. Richer case mix lifts profit per patient, supporting the stock.

    This explains the operational change behind the expected profit growth, not just the headline number.

  • Brokers name PR9 a defensive pick ahead of the Fed meeting Several brokers put PR9 in defensive value and domestic-play lists, citing steady hospital revenue and benefit from a weaker baht, while tech stocks face pressure and markets worry about a possible Fed rate hike. Defensive buying can support the share price even in a shaky market.

    It shows the outside market forces pushing money toward PR9 right now, a real driver of demand for the stock.

Bangkok Dusit Medical Services Public Company Limited (BDMS.BK)

Q3 2026
▲2▼2

BDMS Q3 profit hits record as revenue rebounds, but foreign outflows and floods weigh

  • Record Q3 profit and revenue rebound BDMS reported a record quarterly profit near 4.5 billion baht, with August revenue up 9–10% and occupancy recovering to 65% after a weak Q2. Analysts upgraded target prices to 23.50–25.00 baht.

    This is the main positive driver of the stock's performance in Q3.

  • Weak baht and seasonal illness demand A weaker Thai baht boosted international revenue when converted back to baht, while a flu and COVID wave increased patient volumes. The WellEra wellness project also contributed to growth.

    These are key tailwinds that supported revenue and profit growth.

  • Foreign investor selling and high US yields Foreign investors sold 30.5 billion baht of Thai stocks in seven days, driven by Fed rate hikes that pushed US yields to 5.30%. This created downward pressure on BDMS and the broader market.

    This was a major negative force affecting stock price despite strong company results.

  • Floods and high interest rates cap market Flooding in parts of Thailand and elevated interest rates limited overall market gains and investor sentiment, preventing BDMS from fully benefiting from its operational momentum.

    These external risks acted as a counterweight to the positive company-specific news.

September 2026
▲3▼1

BDMS Surges on Record Q3 Profit and Upgraded Targets

  • Record Q3 Profit and Strong August Revenue BDMS is set to report record Q3 profit near 4.5 billion baht, with August revenue up 9-10% year-on-year, the first double-digit growth since early 2024, driven by Thai, insured, and Middle East patients.

    This is the core new financial performance that drove bullish sentiment and target upgrades.

  • Broker Target Upgrades Major brokers including TISCO, Krungsri, KGI, KKPS, Asia Plus, and CGSI raised their price targets to 23.50-25.00 baht, reflecting confidence in BDMS's earnings recovery and growth outlook.

    Broker upgrades directly influence investor sentiment and can drive buying interest.

  • Multiple Tailwinds Support Growth A weak baht, defensive appeal amid high rates, a flu/COVID wave, tighter FDA control of GLP-1 drugs, a cancer vaccine, flood demand, and a growing wellness market (target: 20% of revenue by 2035) are boosting BDMS's prospects.

    These factors collectively enhance demand and position BDMS favorably in the current environment.

  • Foreign Selling and Macro Risks Foreign investors sold 30.5 billion baht in seven days, and Fed rate hikes pushed US yields to 5.30%, while floods and high rates capped the broader market, posing risks to BDMS's stock performance.

    These external pressures could offset positive company-specific news and weigh on the stock.

Latest
▲3

Brokers pile into BDMS as Q3 profit recovery and defensive appeal build

  • Brokers raise BDMS targets on Q3 profit recovery KKPS, Asia Plus, CGSI and Land and Houses all back BDMS, with targets of 23.50-25.00 baht. They say hospital earnings passed their low point in Q2, August revenue grew 9-10% year-on-year, and Q3 profit should recover both year-on-year and quarter-on-quarter.

    Multiple fresh broker upgrades and higher targets are the main force lifting BDMS shares this period.

  • Flu wave and FDA drug rule lift patient demand Asia Plus says influenza cases jumped to 48,100 in mid-September from 21,753 the week before, with COVID-19 also rising, boosting hospital visits. Separately, tighter FDA control of GLP-1 weight-loss drugs pushes users into standard hospitals, where BDMS has a large network.

    These are new, concrete demand drivers that raise patient volumes and revenue per patient.

  • Cancer vaccine and flood demand add new growth angles Asia Plus flags BDMS as a main beneficiary of a Thai-developed personalized cancer vaccine that could cut treatment costs to about 1 million baht, lifting revenue per cancer patient. Asia Plus and InnovestX also name BDMS as a short-term flood beneficiary and a fast-recovery play.

    New technology and event-driven demand stories give investors fresh reasons to buy BDMS.

  • Defensive status helps, but foreign selling and floods weigh The Fed raised rates to 3.75-4.00%, pushing US 10-year yields to 5.30% and driving 30.5 billion baht of foreign selling in seven days. Brokers still name BDMS a defensive, low-volatility pick, but warn floods and high rates could cap the broader market.

    This is the real counterweight: money leaving Thai stocks limits how far BDMS can rise even with good news.

▲4

BDMS Rides Record Q3 Profit Forecasts and Weak-Baht Tailwind

  • Brokers hike targets on record Q3 profit TISCO raised its BDMS target to 24.50 baht and lifted 2026-2028 earnings forecasts by 7-9%. Krungsri and KGI both see a record third-quarter profit near 4.5 billion baht, up sharply from Q2, as revenue growth accelerates to around 9-10%.

    This is the core new reason the stock is moving: analysts now expect a record profit rebound, not just a bottom.

  • August revenue growth hits 10%, first double-digit since 2024 August hospital revenue grew 10% year-on-year, up from 8% in July, the first double-digit growth since early 2024. Thai patients, insured patients and a recovering Middle East segment are all contributing, easing the drag from Cambodia and Middle East unrest seen in Q2.

    It shows the operational recovery is real and broadening, which underpins the higher profit forecasts.

  • Weak baht and Fed hike make BDMS a defensive pick The baht has weakened past 33 per dollar and the Fed raised rates again, pushing bond yields to multi-year highs. Brokers including Pie, KSS and InnovestX name BDMS among value or defensive stocks that benefit from medical tourism and steady domestic revenue.

    It explains the macro force steering new money into BDMS even as the broad market weakens.

  • Wellness push adds long-term growth story KGI notes Thailand's wellness market is worth $42.7 billion and growing 7-10% a year. BDMS aims to lift wellness to 20% of revenue by 2035 from 12% in 2025, with the WellEra project valued at 26.5 billion baht as a long-term driver.

    It gives a structural reason beyond the current profit cycle for why investors are positive on BDMS.

August 2026
▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

▲3▼1

BDMS Q2 Profit Hits Bottom, July Revenue Jumps 8% on Broad Recovery

  • Q2 profit falls 7% as costs outpace revenue BDMS's second-quarter net profit dropped 7% to 3.25 billion baht. Revenue rose 1%, but costs like doctor fees and depreciation grew faster. International patient income fell 2%, hurt by the Thai-Cambodian border conflict and Middle East unrest, with Cambodian revenue down 67% and Middle Eastern down 24%. Bed occupancy slipped to 55% from 61%.

    This is the period's key negative event, explaining why profit fell and pressuring the stock.

  • July revenue up 8%, occupancy rebounds to 65% BDMS reported July 2026 hospital revenue grew 8% year-on-year, a sharp rebound from just 1% growth in the first half. Bed occupancy rose to 65% from 55% in Q2. Thai patients grew 9%, insured patients 11%, and international patients 6%. Excluding Cambodia and the Middle East, international growth was 14%. Middle East bookings are recovering.

    This is the newest and most important positive driver, showing a clear turnaround that lifts future earnings expectations.

  • Analysts see Q2 as the year's low, keep Buy ratings Asia Plus called Q2/26 the year's lowest point and maintained a Buy with a 22.80 baht target. Bualuang noted BDMS's Q2 results were in line with expectations, with no earnings miss. Bualuang also picked BDMS as a top stock for strong third-quarter profit growth, citing healthcare demand.

    Analyst views frame the weak Q2 as temporary and support the stock's valuation, giving investors confidence.

  • WellEra wellness project to tap global market BDMS is advancing the 29-billion-baht WellEra project on a prime Bangkok plot, including a wellness residence, clinic, and retail. A soft launch is set for Q4 2026, with transfers expected in 2030. Management aims for wellness to contribute 20% of business by 2035, opening a new long-term growth avenue.

    This is a new long-term growth catalyst that could diversify revenue and support future earnings.

© 2026 MarketIVWhy